OncoSec Medical rises on positive data from cancer therapy trial

OncoSec Medical Incorporated

11/11/2022 15:00

** Shares of cancer therapies developer OncoSec Medical Inc
 ONCS.O  up 8.6% at $5.10
    ** Company says mid-stage clinical trial of cancer therapy
TAVO for treating stage 3 or 4 metastatic melanoma patients
meets secondary goal
    ** Metastatic melanoma is a type of skin cancer that
develops from pigment-producing cells in the body
    ** The trial tested TAVO in combination with pmbrolizumab, a
humanized antibody used in cancer immunotherapy
    ** The trial enrolled and collected safety data on 105
patients who had received immediate prior antibody therapy
    ** The combination study was generally well tolerated with
no severe treatment-related adverse events, company says
    ** Trial showed an overall response rate on 18.8%, with
three patients who achieved a complete response and 16 patients
that showed a partial response, according to OncoSec
    ** ONCS expects to post top-line primary endpoint data from
trial in Q1 2023
    ** Including session's gain, stock down ~76% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com))